The Indian Pharmacopoeia Commission (IPC), under the Ministry of Health and Family Welfare, has issued a public notice regarding the National Formulary of India (NFI) 2026. The NFI provides evidence-based guidance to healthcare professionals on the prescribing, dispensing and administration of medicines to promote rational medicine use. It is a guidance document and does not replace applicable statutory provisions or regulatory requirements.
The Indian Pharmacopoeia Commission (IPC) has issued a public notice regarding the National Formulary of India (NFI) 2026, an authoritative reference document intended to promote the rational use of medicines in India. It provides evidence-based guidance to healthcare professionals on prescribing, dispensing and administering medicines to support clinical decision-making and appropriate pharmacotherapy.
Key points include:
- The NFI 2026 serves as a reference for healthcare professionals and is one of the necessary books specified under Schedule N of the Drugs and Cosmetics Act, 1940, and the Rules thereunder, as amended.
- Medicine monographs are selected based on NLEM inclusion, National Health Programme use, CDSCO approval, Indian Pharmacopoeia standards and recommendations from relevant expert panels.
- Inclusion of a particular formulation strength does not mean that other strengths of the same medicine cannot be prescribed.
- Healthcare professionals must exercise professional judgement and follow applicable statutory and regulatory requirements.
- Stakeholders may submit comments and clinical inputs to IPC at lab.ipc@gov.in for future revisions.